1 Ocak 2021 Dergi makalesi Açık Erişim

Ak Aksoy, Secil; Mutlu, Melis; Tunca, Berrin; Kocaeli, Hasan; Taskapilioglu, Mevlut Ozgur; Bekar, Ahmet; Tekin, Cagla; Argadal, Omer Gokay; Civan, Muhammet Nafi; Kaya, Ismail Seckin; Ocak, Pinar Eser; Tolunay, Sahsine

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Mutlu, Melis</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Med Biol, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Tunca, Berrin</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Med Biol, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Kocaeli, Hasan</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Neurosurg, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Taskapilioglu, Mevlut Ozgur</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Neurosurg, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Bekar, Ahmet</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Neurosurg, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Tekin, Cagla</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Med Biol, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Argadal, Omer Gokay</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Neurosurg, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Civan, Muhammet Nafi</subfield>
    <subfield code="u">Uludag Univ, Fac Med, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Kaya, Ismail Seckin</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Neurosurg, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Ocak, Pinar Eser</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Neurosurg, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Tolunay, Sahsine</subfield>
    <subfield code="u">Bursa Uludag Univ, Fac Med, Dept Pathol, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="p">NEUROLOGICAL RESEARCH</subfield>
    <subfield code="v">43</subfield>
    <subfield code="n">11</subfield>
    <subfield code="c">916-925</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.1080/01616412.2021.1948738</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Coexistence of TERT C228T mutation and MALAT1 dysregulation in primary glioblastoma: new prognostic and therapeutic targets</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Ak Aksoy, Secil</subfield>
    <subfield code="u">Bursa Uludag Univ, Inegol Vocat Sch, Bursa, Turkey</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="o">oai:aperta.ulakbim.gov.tr:236606</subfield>
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="2">opendefinition.org</subfield>
    <subfield code="a">cc-by</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2021-01-01</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/236606/files/bib-ed14a5b2-4919-415a-9c31-c0ff7d6b7390.txt</subfield>
    <subfield code="z">md5:82da7d0d39b2e86510c0b345619ac1c3</subfield>
    <subfield code="s">319</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <controlfield tag="005">20221007094229.0</controlfield>
  <controlfield tag="001">236606</controlfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Objective: This study was designed to conduct molecular classification based on IDH1/2, TERT, ATRX, and DAXX changes in pediatric and adult primary glioblastoma (GB) and to analyze the potential interaction of LncRNA MALAT1 in the determined homogeneous subgroups. Methods: We analyzed the expression profiles of ATRX/DAXX and MALAT1 using the qRT-PCR method and IDH and TERT mutation status using DNA sequencing analysis in 85 primary pediatric and adult GB patients. Results: IDH1 mutation was observed in 5 (5.88%) and TERT mutation in 65 (76.47%) primary pediatric and adult GB patients. ATRX and DAXX were detected in 18 (21.18%) and 7 (8.24%) patients. TERT mutation and loss of ATRX/DAXX were associated with short overall survival (p &amp;lt; 0.001, p &amp;lt; 0.001, respectively). Patients carrying especially TERT C228T mutation had worse prognosis (p &amp;lt; 0.001). Six subgroups were obtained from the genetic analysis. Among the subgroups, MALAT1 was highly expressed in group A that had a single TERT mutation as compared to that in groups D and E (p = 0.001 and p &amp;lt; 0.001, respectively); further, high MALAT1 expression was associated with worse prognosis in patients with C228T mutation (p &amp;lt; 0.001). Conclusions: Our findings highlight that the presence of TERT C228T mutation and expression of MALAT1 can be used as primary targets during the follow-up of primary GB patients and in the development of new treatment strategies.</subfield>
  </datafield>
</record>